Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
Morimoto M, Numata K, Moriya S, Kondo M, Nozaki A, Morioka Y, Maeda S, Tanaka K.
Anticancer Res. 2012 Feb;32(2):619-23.
Related citations
Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion.
Chun YH, Ahn SH, Park JY, Kim do Y, Han KH, Chon CY, Byun SJ, Kim SU.
Anticancer Res. 2011 Dec;31(12):4641-6.
Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience.
Giorgio A, Calisti G, DE Stefano G, Farella N, DI Sarno A, Amendola F, Scognamiglio U, Giorgio V.
Anticancer Res. 2011 Dec;31(12):4575-80.
Initial experience with hepatic intraarterial fotemustine and interferon alpha 2b combination for treatment of liver tumors.
Vitale FV, Romeo P, DI Maggio EM, Parisi A, Malaponte E, Calì S, Vasta F, Panebianco V, Arcoria D, Ferraù F.
Anticancer Res. 2011 Dec;31(12):4553-9.
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma.
Shao YY, Chen PJ, Lin ZZ, Huang CC, Ding YH, Lee YH, Hsu CH, Cheng AL.
Anticancer Res. 2011 Nov;31(11):4007-11.
Resection of solitary metachronous lymph node metastasis from hepatocellular carcinoma following transarterial chemotherapy with cisplatin: a case report.
Kurokawa T, Yamazaki S, Moriguchi M, Aoki M, Watanabe Y, Higaki T, Takayama T.
Anticancer Res. 2011 Nov;31(11):3991-3.
Characterization of dysplastic nodules, early hepatocellular carcinoma and progressed hepatocellular carcinoma in cirrhosis with contrast-enhanced ultrasound.
Giorgio A, Calisti G, di Sarno A, Farella N, de Stefano G, Scognamiglio U, Giorgio V.
Anticancer Res. 2011 Nov;31(11):3977-82.
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Poggi G, Montagna B, Melchiorre F, Quaretti P, Delmonte A, Riccardi A, Tagliaferri B, Sottotetti F, Di Cesare P, Stella MG, Villani L, Zorzetto M, Greco G, Cornalba G, Bernardo G.
Anticancer Res. 2011 Nov;31(11):3927-33.
Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma.
Hoffmann K, Shibo L, Xiao Z, Longerich T, Büchler MW, Schemmer P.
Anticancer Res. 2011 Nov;31(11):3883-90.
Expression of zinc finger 23 gene in human hepatocellular carcinoma.
Shi Y, Zheng L, Luo G, Wei J, Zhang J, Yu Y, Feng Y, Li M, Xu N.
Anticancer Res. 2011 Oct;31(10):3595-9.
Thiamine supplementation attenuated hepatocellular carcinoma in the Atp7b mouse model of Wilson's disease.
Sheline CT.
Anticancer Res. 2011 Oct;31(10):3395-9.
Up-regulation of 42 kDa tubulin alpha-6 chain fragment in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus.
Kuramitsu Y, Takashima M, Yokoyama Y, Iizuka N, Tamesa T, Akada JK, Wang Y, Toda T, Sakaida I, Okita K, Oka M, Nakamura K.
Anticancer Res. 2011 Oct;31(10):3331-6.
Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
Okabe K, Beppu T, Haraoka K, Oh-Uchida Y, Yamamura S, Tomiyasu S, Yamanaka T, Sano O, Masuda T, Chikamoto A, Fujiyama S, Baba H.
Anticancer Res. 2011 Sep;31(9):2983-8.
Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis.
Gundling F, Seidl H, Schmidtler F, Löffler N, Strassen I, Wolf P, Pehl C, Schmidt T, Schepp W.
Anticancer Res. 2011 Sep;31(9):2931-8.
Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas.
Henderson-Jackson EB, Helm J, Strosberg J, Nasir NA, Yeatman TJ, Kvols LK, Coppola D, Nasir A.
Anticancer Res. 2011 Sep;31(9):2957-62.
CT-guided high-dose-rate brachytherapy of metachronous ovarian cancer metastasis to the liver: initial experience.
Collettini F, Poellinger A, Schnapauff D, Denecke T, Wust P, Braicu IE, Sehouli J, Hamm B, Gebauer B.
Anticancer Res. 2011 Aug;31(8):2597-602.
Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system.
Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I, Katano M.
Anticancer Res. 2011 Jul;31(7):2505-10.
Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial.
Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farella N, Mariniello A, Esposito V, Coppola C, Giorgio V.
Anticancer Res. 2011 Jun;31(6):2291-5. Erratum in: Anticancer Res. 2012 Mar;32(3):1117.
Identification of differentially expressed proteins in tumour necrosis factor-alpha-resistant and -sensitive rat hepatoma cells.
Kuramitsu Y, Zhang X, Wang Y, Nakamura K.
Anticancer Res. 2011 Jun;31(6):2059-63.
Predicting response to benzamide riboside chemotherapy in hepatocellular carcinoma using apparent diffusion coefficient of water.
Babsky AM, Ju S, George B, Bennett S, Huang M, Jayaram HN, McLennan G, Bansal N.
Anticancer Res. 2011 Jun;31(6):2045-51.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on